Status | Study |
Recruiting |
Study Name: Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets Condition: Desmoid Type-fibromatosis Date: 2015-01-28 Interventions: Drug: Toremifene Patients will receive 60 mg daily and then 180 daily in case of progression |
Active, not recruiting |
Study Name: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Condition: Desmoid-Type Fibromatosis Date: 2014-02-17 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma Condition: Solitary Fibrous Tumor Extraskeletal Myxoid Chondrosarcoma Date: 2014-02-14 Interventions: Drug: Pazopanib Treatment will continue until disease progression, development of unacceptable toxicity, |
Not yet recruiting |
Study Name: Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor Condition: Solitary Fibrous Tumor Date: 2014-01-30 Interventions: Drug: Axitinib Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment wil |
Recruiting |
Study Name: Peripheral Primitive Fibromatosis Condition: Peripheral Primitive Fibromatosis Date: 2013-02-25 Interventions: Other: MRI MRI every 3 months during the first year and then every 6 months during the second year and t |
Active, not recruiting |
Study Name: Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura. Condition: Solitary Fibrous Tumors of the Pleura Date: 2012-09-24 |
Recruiting |
Study Name: A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Condition: Desmoid Tumor Date: 2010-12-06 Interventions: Drug: Sirolimus Loading do |
Withdrawn |
Study Name: Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors Condition: Desmoid Tumors Fibromatosis Date: 2009-09-15 Interventions: Drug: Hydroxyurea Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients w |
Active, not recruiting |
Study Name: Trial of Dasatinib in Advanced Sarcomas Condition: Rhabdomyosarcoma Malignant Peripheral Nerve Sheath Tumors Date: 2007-04-20 Interventions: Drug: Dasatinib oral agent, continuous dosing, Cycles = 28 days |
Completed |
Study Name: Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Condition: Childhood Malignant Fibrous Histiocytoma of Bone Sarcoma Date: 2007-03-20 Interventions: Drug: celecoxib Procedure: adjuvant therap |